EA201792032A1 - ANTI-PDL1-ANTIBODIES ACTIVATED TO ANTI-PDL1-ANTIBODIES AND METHODS OF THEIR APPLICATION - Google Patents

ANTI-PDL1-ANTIBODIES ACTIVATED TO ANTI-PDL1-ANTIBODIES AND METHODS OF THEIR APPLICATION

Info

Publication number
EA201792032A1
EA201792032A1 EA201792032A EA201792032A EA201792032A1 EA 201792032 A1 EA201792032 A1 EA 201792032A1 EA 201792032 A EA201792032 A EA 201792032A EA 201792032 A EA201792032 A EA 201792032A EA 201792032 A1 EA201792032 A1 EA 201792032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pdl1
antibodies
activated
methods
application
Prior art date
Application number
EA201792032A
Other languages
Russian (ru)
Other versions
EA039736B1 (en
Inventor
Джеймс Уилльям Уэст
Ли Мей
Стефен Джеймс Мур
Маргарет Нгуйен
Дэниел Хостеттер
Ольга ВАСИЛЬЕВА
Джейсон Сэйджерт
Джонатан Терретт
Original Assignee
Сайтомкс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайтомкс Терапьютикс, Инк. filed Critical Сайтомкс Терапьютикс, Инк.
Priority claimed from PCT/US2016/022345 external-priority patent/WO2016149201A2/en
Publication of EA201792032A1 publication Critical patent/EA201792032A1/en
Publication of EA039736B1 publication Critical patent/EA039736B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится, в общем, к антителам, которые связываются с лигандом 1 полипептида программируемой смерти (PDL1), к активируемым антителам, которые специфически связываются с PDL1, и способам получения и применения этих анти-PDL1-антител и активируемых анти-PDL1-антител в различных терапевтических, диагностических и профилактические показаниях.The invention relates in general to antibodies that bind to a programmable death polypeptide ligand 1 (PDL1), to activated antibodies that specifically bind to PDL1, and to methods for producing and using these anti-PDL1 antibodies and activated anti-PDL1 antibodies in various therapeutic, diagnostic and prophylactic indications.

EA201792032A 2015-09-15 2016-03-14 Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof EA039736B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218883P 2015-09-15 2015-09-15
PCT/US2016/022345 WO2016149201A2 (en) 2015-03-13 2016-03-14 Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201792032A1 true EA201792032A1 (en) 2018-04-30
EA039736B1 EA039736B1 (en) 2022-03-04

Family

ID=81077508

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792032A EA039736B1 (en) 2015-09-15 2016-03-14 Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof

Country Status (1)

Country Link
EA (1) EA039736B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359551B (en) * 2009-11-24 2018-10-02 Medimmune Ltd Targeted binding agents against b7-h1.
SG11201406943XA (en) * 2012-04-27 2014-12-30 Cytomx Therapeutics Inc Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US11161906B2 (en) * 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same

Also Published As

Publication number Publication date
EA039736B1 (en) 2022-03-04

Similar Documents

Publication Publication Date Title
MX2021013467A (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof.
EA201792413A1 (en) ANTIBODIES AGAINST CD71, ACTIVATED ANTIBODIES AGAINST CD71 AND METHODS OF THEIR APPLICATION
CY1122840T1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
EA201792414A1 (en) ANTIBODIES AGAINST CD166, ACTIVATED ANTIBODIES AGAINST CD166 AND METHODS OF THEIR APPLICATION
NZ759442A (en) Activatable anti-pdl1 antibodies, and methods of use thereof
EA201892294A1 (en) ANTIBODIES AND COMPOSITIONS AGAINST TIM-3
EA201791139A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
PH12016501644B1 (en) Binding proteins and methods of use thereof
EA201791164A1 (en) HETERODIMERIC ANTIBODIES CONNECTING CD3 AND CD38
EA201890131A1 (en) IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38
EA201792467A1 (en) HETERODIMERNYE ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
MX2017004311A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
EA201791029A1 (en) ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201890305A1 (en) HUMANIZED OR CHIMERIC CD3 ANTIBODIES
JOP20160131B1 (en) Factor xi antibodies and methods of use
NZ738008A (en) Tigit-binding agents and uses thereof
EA201790569A1 (en) ANTIBODIES AND IMMUNOCONJUGATES AGAINST CLL-1
EA201790545A1 (en) ANTIBODIES AND IMMUNOCONJUGATES AGAINST HER2
EA201692394A1 (en) ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES
BR112016022658A2 (en) anti-ox40 antibodies and methods of use
EA201691610A8 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION